OBiO Tech(SH:688238)2025-04-23 09:55Financial Performance - The company's revenue for Q1 2025 was ¥52,847,732.33, representing a decrease of 11.29% compared to ¥59,574,128.09 in the same period last year[3] - The net profit attributable to shareholders was -¥59,477,301.44, an increase in loss compared to -¥42,170,292.32 in the previous year[3] - The net cash flow from operating activities was -¥61,413,681.55, slightly improved from -¥62,542,304.19 in the previous year[3] - The weighted average return on equity was -3.48%, a decrease of 1.39 percentage points from -2.09%[3] - The company experienced a decline in revenue primarily due to decreased income from its cell and gene therapy CDMO business[6] - The company achieved a total revenue of RMB 52.85 million, a decrease of 11.29% compared to the same period last year[11] - The revenue from cell and gene therapy CRO business was RMB 19.86 million, an increase of 10.59% year-on-year, indicating stable growth[11] - The revenue from cell and gene therapy CDMO business was RMB 27.61 million, a decrease of 27.74% year-on-year, primarily due to the types of CDMO orders executed during the reporting period[11] - New CDMO orders exceeded RMB 28 million during the reporting period, with the company assisting clients in obtaining 2 IND approvals in the US and China[11] - Net loss for Q1 2025 was CNY 59,510,258.38, compared to a net loss of CNY 42,298,770.28 in Q1 2024, indicating an increase in losses of 40.6%[20] - The net profit attributable to shareholders of the parent company for Q1 2025 was CNY -59,477,301.44, compared to CNY -42,170,292.32 in Q1 2024, representing a 40.9% increase in losses[21] - Basic and diluted earnings per share for Q1 2025 were both CNY -0.092, compared to CNY -0.066 in Q1 2024[21] Research and Development - The total R&D investment was ¥10,820,956.46, down 23.00% from ¥14,053,882.62 year-on-year, with R&D expenses accounting for 20.48% of revenue[4] - The company plans to optimize its R&D personnel structure and focus on core projects, leading to reduced R&D spending[6] - Research and development expenses for Q1 2025 were CNY 10,820,956.46, down from CNY 14,053,882.62 in Q1 2024, a reduction of 23.5%[20] - The company’s R&D expenses for Q1 2025 were ¥2,257,223.97, down from ¥4,154,358.16 in Q1 2024, a reduction of 45.38%[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,194,350,719.20, a decrease of 3.96% from ¥2,284,740,741.02 at the end of the previous year[4] - The total assets of the company as of March 31, 2025, were RMB 2.19 billion, a decrease from RMB 2.28 billion at the end of 2024[16] - Total liabilities as of the end of the reporting period were CNY 571,887,808.95, an increase from CNY 545,193,225.79 at the end of the previous period[17] - The total equity attributable to shareholders of the parent company was CNY 1,622,740,580.83, down from CNY 1,739,792,228.87, a decrease of 6.7%[17] - The total current assets increased to ¥1,055,705,282.14 as of March 31, 2025, compared to ¥1,022,034,773.67 at the end of 2024, reflecting a growth of 3.63%[28] - The total liabilities increased to ¥285,590,552.30 as of March 31, 2025, compared to ¥185,513,971.89 at the end of 2024, indicating a growth of 54.00%[29] Cash Flow and Financing - As of March 31, 2025, the company had cash and cash equivalents of RMB 360.04 million, down from RMB 439.44 million at the end of 2024[15] - The cash and cash equivalents at the end of the period were ¥355,486,612.35, down from ¥562,880,278.98 at the end of the previous period, representing a decrease of 36.83%[25] - The company received cash from investment activities totaling ¥90,580,816.32, significantly higher than ¥28,685,449.94 in the previous period[25] - The cash outflow from investment activities was ¥150,952,902.19, an increase from ¥112,499,033.84 in the previous period[25] - The cash flow from financing activities in Q1 2025 was 49,471,025.59 RMB, compared to 58,191,094.73 RMB in Q1 2024, indicating a decrease of about 15%[34] - The company paid 71,233,500.00 RMB in debt repayments during Q1 2025, a significant increase from 1,233,500.00 RMB in Q1 2024[34] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,799[8] - The largest shareholder, Pan Oudong, holds 18.92% of the shares, totaling 122,805,540 shares[8] Other Developments - The company completed a share buyback of 18,726,690 shares for a total payment of RMB 99.94 million[14] - The company registered 3 new domestic trademarks and applied for 2 invention patents and 6 utility model patents during the reporting period[12] - The company’s long-term equity investments amounted to RMB 66.61 million as of March 31, 2025, slightly up from RMB 66.34 million at the end of 2024[16] - The company’s short-term borrowings increased significantly to RMB 180.75 million from RMB 70.05 million at the end of 2024[16]